-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Maintains Neutral on Tandem Diabetes Care, Raises Price Target to $22

Benzinga·02/20/2026 16:09:28
Listen to the news
UBS analyst Danielle Antalffy maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Neutral and raises the price target from $17 to $22.